ProfileGDS5678 / 1425404_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 38% 40% 40% 41% 57% 37% 37% 40% 40% 40% 40% 41% 40% 43% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9186438
GSM967853U87-EV human glioblastoma xenograft - Control 22.9175140
GSM967854U87-EV human glioblastoma xenograft - Control 32.9202840
GSM967855U87-EV human glioblastoma xenograft - Control 42.8814941
GSM967856U87-EV human glioblastoma xenograft - Control 53.413757
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9375637
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.913337
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9085240
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8985740
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.915440
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9006340
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9013441
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9188640
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9809643